Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement

3 years ago

Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline’s anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED)…

Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention

3 years ago

SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that Eboo…

Bitech Technologies Empowers Sustainable Growth with Entry into Energy Storage System (ESS) Markets

3 years ago

Newport Beach, CA, June 22, 2023 (GLOBE NEWSWIRE) -- Bitech Technologies Corporation [OTCQB: BTTC], a global technology solution provider dedicated…

Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management

3 years ago

Proceeds to Be Used to Redeem All of the Outstanding 5.75% Convertible Unsecured Senior Notes This news release constitutes a…

XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset

3 years ago

New Drug Application for arimoclomol in NPC to be filed as early as the third quarter of 2023¹EMERYVILLE, Calif., June 22,…

Avicanna Sponsors New Medical Cannabis Education and Training Campaign in Canada with the Canadian Consortium for the Investigation of Cannabinoids (“CCIC”)

3 years ago

Through a sponsorship agreement CCIC’s accredited Canadian Cannabis Syllabus will be made available to the medical community Avicanna Sponsors New…

ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan

3 years ago

ASLAN will receive up to $15 million in upfront and near-term payments and up to an additional $123.5 million based…

Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period

3 years ago

This is the first-ever long-duration data reported for an anti-TL1A antibodyAt the expected Phase 3 once-monthly subcutaneous dose in the…

Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association

3 years ago

The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the safety and efficacy of AT-001 (caficrestat) in improving or…

Montauk Brewing Company Celebrates 11-Year Anniversary and Announces 2023 Summer Season Lineup

3 years ago

New York’s Leading Craft Brewer Introduces New Summer Beers and Expands Brew Barn Bar Locations Across Popular Venues Montauk Launches…